Serum prolidase activity and oxidant–antioxidant status in children with chronic hepatitis B virus infection

Table 2 Prolidase activity and oxidative–antioxidative status in the study groups (mean ± standard deviation)

	Chronic hepatitis B (n = 38)	Inactive hepatitis B (n = 31)	Controls (n = 29)	^*p
SPEA (IU/L)	207.8 ± 186.8^a,e	67.1 ± 39.9	58.6 ± 38.1	<0.001
MDA (μm/L)	13.3 ± 4.0^a,h	7.8 ± 3.6	7.8 ± 2.6	<0.001
TAC (μmol Trolox Eq t/l)	1.77 ± 0.90^b	2.28 ± 0.88	2.46 ± 0.67	0.015
TOA (μmolH₂O₂ Eq./L)	45.0 ± 19.9^c,f	32.0 ± 10.0	29.4 ± 11.7	0.001
OSI (H₂O₂/Trolox)	33.1 ± 21.4^d,g	15.4 ± 11.0	17.5 ± 10.2	<0.001

CHB: Chronic Hepatitis B, IHB: Inactive Hepatitis B, SPEA: Serum prolidase enzyme activity, TAC: Total antioxidant capacity, TOA: Total oxidant activity, OSI (Arbitrary Unite): Oxidative stress index, and MDA: Malondialdehyde.
^*Difference between three groups with Kruskal-Wallis test.
Differences between pairwise groups with Mann–Whitney U test:
^aCompared with group control (p < 0.001).
^bCompared with group control (p = 0.004).
^cCompared with group control (p = 0.005).
^dCompared with group control (p = 0.002).
^eCompared with group IHB (p < 0.001).
^fCompared with group IHB (p = 0.001).
^gCompared with group IHB (p < 0.001).
^hCompared with group IHB (p < 0.001).

ISSN: 1824-7288